Table 1.
Characteristics of included studies
| Trials | Year of publication |
Total randomised |
Type of valves |
Number Randomised |
Patients Characteristics | Local of prosthesis implantation |
Follow-up (m/y) |
|---|---|---|---|---|---|---|---|
| Vallejo | 1981 | 110 | Bioprosthesis: Angell-Shiley |
38 | 7% NYHA II; 27% NYHA III; 4% NYHA IV 66% Male, Mean age: 39.7 ± 11 .2 |
MVR | Mean 24.13 ±11.16 m |
| Mechanical prosthesis *: Bjork-Shiley |
35 | 7% NYHA II; 24% NYHA III; 4% NYHA IV 69% Male, 40.7 ± 11.3 |
MVR | Mean 31.61 ± 13.02 m |
|||
| Lillehei-Kaster | 37 | 4% NYHA II; 30% NYHA III; 3% NYHA IV 76% Male, 41.9 ± 10.4 |
MVR | Mean 30.4 ± 15.9 m |
|||
| Veterans
Affairs (Hammermeister) |
2000 | 575 | Bioprosthesis: Hancock porcine |
289 | 100% Male | 67% AVR; 33% MVR |
Maximum 18 y |
| Mechanical prosthesis: Bjork-Shiley |
286 | 100% Male | 69% AVR; 31% MVR |
Maximum 18 y | |||
| Edinburgh (Oxenham, Bloomfield) |
2003 | 533 | Bioprosthesis: Hancock porcine Carpentier- Edwards |
107 159 |
53% NYHA III or IV AF † 76% Female mitral valve |
38% AVR, 50% MVR, 12% AVR+MVR |
Mean 20.4 y |
| Mechanical prosthesis: Bjork-Shiley |
267 | 57% NYHA III or IV 74% Female mitral valve |
41% AVR, 48% MVR, 11% AVR+MVR |
Mean 20.4 y |
|||
| Stassano | 2009 | 310 | Bioprosthesis: Carpentier- Edwards SAV |
93 | 75.5% NYHA III or IV Male 50.3% Age 63.5 ± 3.9 |
100% AVR | Mean 106 ± 28 m |
| Carpentier- Edwards Pericardial |
62 | ||||||
| Mechanical prosthesis: St. Jude Medical |
107 | 76,8% NYHA III or IV Male 42,5% Age 64.0 ± 7.6 |
|||||
| Carbomedics | 48 |
*
Tilting disc valve. 37.8% previous surgery in mitral valve with LK (p < 0.005);
†
67% Bioprosthesis in atrial fibrillation.